 Victoria Pelak
Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 12 | 2026 | 616 | 3.350 |
Why?
| | Vision Disorders | 14 | 2025 | 175 | 3.160 |
Why?
| | Neurodegenerative Diseases | 4 | 2022 | 146 | 1.730 |
Why?
| | Visual Pathways | 4 | 2025 | 61 | 1.450 |
Why?
| | Visual Perception | 3 | 2025 | 183 | 1.400 |
Why?
| | Atrophy | 8 | 2025 | 199 | 1.260 |
Why?
| | Cerebral Cortex | 7 | 2025 | 467 | 1.240 |
Why?
| | Eye Movements | 3 | 2021 | 92 | 1.150 |
Why?
| | Aging | 4 | 2026 | 1972 | 0.850 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2024 | 9 | 0.830 |
Why?
| | Eye Diseases | 2 | 2020 | 94 | 0.800 |
Why?
| | Lewy Body Disease | 2 | 2020 | 33 | 0.740 |
Why?
| | Inflammation | 2 | 2026 | 2900 | 0.720 |
Why?
| | Neurology | 2 | 2024 | 110 | 0.700 |
Why?
| | Nervous System Diseases | 2 | 2020 | 281 | 0.690 |
Why?
| | Posterior Leukoencephalopathy Syndrome | 1 | 2021 | 10 | 0.690 |
Why?
| | Tremor | 2 | 2021 | 98 | 0.690 |
Why?
| | Cognitive Dysfunction | 3 | 2023 | 454 | 0.680 |
Why?
| | Ocular Motility Disorders | 4 | 2018 | 41 | 0.670 |
Why?
| | Dementia | 3 | 2023 | 298 | 0.660 |
Why?
| | Fragile X Syndrome | 1 | 2021 | 118 | 0.660 |
Why?
| | Health Status | 1 | 2026 | 821 | 0.650 |
Why?
| | Reading | 1 | 2021 | 135 | 0.630 |
Why?
| | Macular Degeneration | 1 | 2022 | 190 | 0.620 |
Why?
| | Mucolipidoses | 1 | 2019 | 9 | 0.610 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 386 | 0.560 |
Why?
| | Tomography, Optical Coherence | 4 | 2022 | 263 | 0.560 |
Why?
| | Coronavirus Infections | 2 | 2020 | 383 | 0.550 |
Why?
| | Betacoronavirus | 2 | 2020 | 289 | 0.550 |
Why?
| | Visual Fields | 5 | 2022 | 117 | 0.510 |
Why?
| | Ophthalmology | 1 | 2018 | 116 | 0.500 |
Why?
| | Migraine Disorders | 1 | 2018 | 109 | 0.500 |
Why?
| | Androgens | 1 | 2016 | 187 | 0.440 |
Why?
| | Humans | 54 | 2026 | 144228 | 0.410 |
Why?
| | Optic Neuropathy, Ischemic | 3 | 2012 | 31 | 0.410 |
Why?
| | Magnetic Resonance Imaging | 11 | 2024 | 3842 | 0.400 |
Why?
| | Visual Acuity | 7 | 2023 | 486 | 0.380 |
Why?
| | Pandemics | 2 | 2020 | 1682 | 0.370 |
Why?
| | Testosterone | 1 | 2016 | 427 | 0.370 |
Why?
| | Optic Neuritis | 3 | 2020 | 43 | 0.300 |
Why?
| | Optic Nerve Diseases | 2 | 2009 | 49 | 0.300 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2020 | 53 | 0.300 |
Why?
| | Vision, Low | 1 | 2009 | 17 | 0.300 |
Why?
| | Cognition | 2 | 2023 | 1255 | 0.300 |
Why?
| | Optic Nerve | 1 | 2009 | 65 | 0.290 |
Why?
| | Middle Aged | 21 | 2026 | 35731 | 0.290 |
Why?
| | Male | 28 | 2026 | 71757 | 0.290 |
Why?
| | Aged | 15 | 2026 | 25675 | 0.280 |
Why?
| | Giant Cell Arteritis | 3 | 2020 | 46 | 0.260 |
Why?
| | Brain Diseases | 2 | 2017 | 152 | 0.260 |
Why?
| | Congresses as Topic | 2 | 2019 | 228 | 0.260 |
Why?
| | Female | 28 | 2026 | 77795 | 0.250 |
Why?
| | Chemokine CXCL5 | 1 | 2026 | 19 | 0.240 |
Why?
| | Amyloid beta-Peptides | 2 | 2026 | 238 | 0.240 |
Why?
| | Chemokine CXCL9 | 1 | 2026 | 38 | 0.240 |
Why?
| | Cataract Extraction | 1 | 2006 | 119 | 0.220 |
Why?
| | Nerve Net | 2 | 2022 | 277 | 0.210 |
Why?
| | Pseudotumor Cerebri | 2 | 2016 | 32 | 0.210 |
Why?
| | Adult | 16 | 2026 | 40230 | 0.210 |
Why?
| | Cognition Disorders | 2 | 2023 | 542 | 0.200 |
Why?
| | Biomarkers | 3 | 2026 | 4258 | 0.200 |
Why?
| | Cerebral Hemorrhage | 1 | 2024 | 119 | 0.190 |
Why?
| | Cognitive Aging | 1 | 2023 | 18 | 0.190 |
Why?
| | Putamen | 1 | 2002 | 22 | 0.190 |
Why?
| | Interferon-gamma | 1 | 2026 | 792 | 0.190 |
Why?
| | Methanol | 1 | 2002 | 46 | 0.190 |
Why?
| | Brain Edema | 1 | 2002 | 62 | 0.180 |
Why?
| | Lewy Bodies | 1 | 2022 | 10 | 0.180 |
Why?
| | Unconsciousness | 1 | 2022 | 22 | 0.180 |
Why?
| | Phacoemulsification | 1 | 2023 | 122 | 0.180 |
Why?
| | Immunosuppressive Agents | 4 | 2020 | 844 | 0.180 |
Why?
| | Interleukin-6 | 1 | 2026 | 791 | 0.180 |
Why?
| | Amnesia | 2 | 2012 | 47 | 0.180 |
Why?
| | Brain | 7 | 2024 | 2909 | 0.170 |
Why?
| | Ataxia | 1 | 2021 | 67 | 0.170 |
Why?
| | Neuropsychological Tests | 3 | 2022 | 1125 | 0.170 |
Why?
| | Diffusion Tensor Imaging | 2 | 2023 | 75 | 0.170 |
Why?
| | White Matter | 1 | 2023 | 151 | 0.170 |
Why?
| | Trochlear Nerve Diseases | 1 | 2001 | 8 | 0.170 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2001 | 14 | 0.170 |
Why?
| | Abducens Nerve Diseases | 1 | 2001 | 13 | 0.170 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 121 | 0.170 |
Why?
| | Cataract | 1 | 2023 | 237 | 0.170 |
Why?
| | Myasthenia Gravis | 1 | 2020 | 23 | 0.160 |
Why?
| | Stents | 2 | 2016 | 546 | 0.160 |
Why?
| | Autonomic Fibers, Preganglionic | 1 | 1999 | 3 | 0.160 |
Why?
| | Siderosis | 1 | 1999 | 3 | 0.160 |
Why?
| | Eye Movement Measurements | 1 | 2019 | 14 | 0.150 |
Why?
| | Pupil | 1 | 1999 | 22 | 0.150 |
Why?
| | Brain Stem | 1 | 2000 | 96 | 0.150 |
Why?
| | West Nile Fever | 1 | 2020 | 57 | 0.150 |
Why?
| | Immunomodulation | 1 | 2020 | 102 | 0.150 |
Why?
| | Retrospective Studies | 8 | 2024 | 16805 | 0.150 |
Why?
| | Steroids | 1 | 2020 | 161 | 0.150 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 153 | 0.150 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2019 | 53 | 0.150 |
Why?
| | Hearing Loss | 1 | 2023 | 244 | 0.150 |
Why?
| | Immune System | 1 | 2020 | 182 | 0.140 |
Why?
| | San Francisco | 1 | 2018 | 60 | 0.140 |
Why?
| | Facial Recognition | 1 | 2019 | 35 | 0.140 |
Why?
| | Facial Expression | 1 | 2019 | 74 | 0.140 |
Why?
| | Frontotemporal Dementia | 1 | 2019 | 57 | 0.140 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2018 | 63 | 0.130 |
Why?
| | Transverse Sinuses | 1 | 2016 | 9 | 0.130 |
Why?
| | Epilepsy, Temporal Lobe | 1 | 2017 | 37 | 0.130 |
Why?
| | Vestibule, Labyrinth | 1 | 2018 | 91 | 0.130 |
Why?
| | Postoperative Complications | 2 | 2023 | 2904 | 0.120 |
Why?
| | Aged, 80 and over | 2 | 2026 | 8154 | 0.120 |
Why?
| | Papilledema | 2 | 2018 | 43 | 0.120 |
Why?
| | Universities | 1 | 2018 | 455 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2021 | 3618 | 0.120 |
Why?
| | Amygdala | 1 | 2017 | 199 | 0.110 |
Why?
| | Immunotherapy | 1 | 2020 | 670 | 0.110 |
Why?
| | Laser Therapy | 1 | 2017 | 136 | 0.110 |
Why?
| | Critical Care | 1 | 2021 | 699 | 0.110 |
Why?
| | Brain Mapping | 3 | 2022 | 536 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1048 | 0.100 |
Why?
| | Optic Disk Drusen | 1 | 2012 | 6 | 0.090 |
Why?
| | Autoantibodies | 2 | 2018 | 1497 | 0.090 |
Why?
| | Biomedical Research | 1 | 2019 | 714 | 0.090 |
Why?
| | Multiple Sclerosis | 3 | 2020 | 483 | 0.090 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2023 | 155 | 0.090 |
Why?
| | Cranial Sinuses | 1 | 2011 | 15 | 0.090 |
Why?
| | Hemianopsia | 1 | 2011 | 11 | 0.090 |
Why?
| | Visual Field Tests | 1 | 2011 | 34 | 0.090 |
Why?
| | Optic Disk | 2 | 2009 | 53 | 0.090 |
Why?
| | Parkinson Disease | 1 | 2018 | 595 | 0.090 |
Why?
| | Risk Factors | 1 | 2026 | 10641 | 0.090 |
Why?
| | Memory, Episodic | 1 | 2012 | 54 | 0.090 |
Why?
| | Hemodynamics | 1 | 2016 | 1116 | 0.090 |
Why?
| | Hippocampus | 1 | 2017 | 968 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2009 | 1503 | 0.080 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 202 | 0.080 |
Why?
| | Quality of Life | 1 | 2022 | 3146 | 0.080 |
Why?
| | Hypokinesia | 1 | 2008 | 11 | 0.070 |
Why?
| | Nervous System Malformations | 1 | 2009 | 46 | 0.070 |
Why?
| | Stiff-Person Syndrome | 1 | 2008 | 13 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2017 | 5327 | 0.070 |
Why?
| | Age of Onset | 2 | 2020 | 543 | 0.070 |
Why?
| | Rest | 2 | 2022 | 128 | 0.060 |
Why?
| | Arteritis | 1 | 2006 | 25 | 0.060 |
Why?
| | Spinal Nerve Roots | 1 | 2005 | 29 | 0.060 |
Why?
| | Aphasia, Primary Progressive | 1 | 2024 | 2 | 0.060 |
Why?
| | Cranial Nerve Diseases | 1 | 2005 | 43 | 0.060 |
Why?
| | Neuropsychiatry | 1 | 2024 | 17 | 0.050 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2005 | 133 | 0.050 |
Why?
| | Blindness, Cortical | 1 | 2003 | 6 | 0.050 |
Why?
| | Animals | 4 | 2023 | 38231 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 2097 | 0.050 |
Why?
| | Gliosis | 1 | 2023 | 29 | 0.050 |
Why?
| | Demography | 1 | 2024 | 289 | 0.050 |
Why?
| | Neurites | 1 | 2023 | 50 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 320 | 0.050 |
Why?
| | Levodopa | 1 | 2002 | 40 | 0.050 |
Why?
| | Pulvinar | 1 | 2022 | 3 | 0.050 |
Why?
| | Adolescent | 6 | 2020 | 22282 | 0.050 |
Why?
| | Necrosis | 1 | 2002 | 244 | 0.040 |
Why?
| | Pre-Eclampsia | 1 | 2003 | 203 | 0.040 |
Why?
| | Young Adult | 4 | 2022 | 13949 | 0.040 |
Why?
| | Diplopia | 1 | 2001 | 27 | 0.040 |
Why?
| | Treatment Failure | 2 | 2016 | 363 | 0.040 |
Why?
| | Neuroimaging | 1 | 2023 | 288 | 0.040 |
Why?
| | Functional Laterality | 1 | 2022 | 242 | 0.040 |
Why?
| | Connectome | 1 | 2022 | 90 | 0.040 |
Why?
| | Vision Tests | 1 | 2000 | 22 | 0.040 |
Why?
| | Strabismus | 1 | 2001 | 70 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2020 | 87 | 0.040 |
Why?
| | Vision, Ocular | 1 | 2000 | 46 | 0.040 |
Why?
| | Temporal Lobe | 2 | 2012 | 105 | 0.040 |
Why?
| | Cohort Studies | 2 | 2024 | 5876 | 0.040 |
Why?
| | Demyelinating Diseases | 1 | 2020 | 84 | 0.040 |
Why?
| | Intubation, Intratracheal | 1 | 2002 | 312 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2002 | 1266 | 0.040 |
Why?
| | New Orleans | 1 | 2019 | 15 | 0.040 |
Why?
| | Suicide, Attempted | 1 | 2002 | 380 | 0.040 |
Why?
| | Eye Pain | 1 | 2018 | 6 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2018 | 46 | 0.040 |
Why?
| | Encephalitis | 1 | 2020 | 139 | 0.030 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 303 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2023 | 11501 | 0.030 |
Why?
| | Recurrence | 1 | 2020 | 1123 | 0.030 |
Why?
| | Transfection | 1 | 2018 | 952 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 752 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2003 | 2788 | 0.030 |
Why?
| | Focus Groups | 1 | 2018 | 574 | 0.030 |
Why?
| | Hospital Mortality | 1 | 1999 | 978 | 0.030 |
Why?
| | Patient Participation | 1 | 2018 | 436 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2018 | 1193 | 0.030 |
Why?
| | Child, Preschool | 2 | 2020 | 11656 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2018 | 899 | 0.030 |
Why?
| | Emotions | 1 | 2019 | 577 | 0.020 |
Why?
| | Child | 3 | 2020 | 22493 | 0.020 |
Why?
| | Risk Assessment | 1 | 2002 | 3560 | 0.020 |
Why?
| | Disease Management | 1 | 2016 | 639 | 0.020 |
Why?
| | Color Vision Defects | 1 | 2012 | 8 | 0.020 |
Why?
| | Spinal Puncture | 1 | 2012 | 18 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4591 | 0.020 |
Why?
| | Phlebography | 1 | 2011 | 40 | 0.020 |
Why?
| | Cerebral Angiography | 1 | 2011 | 118 | 0.020 |
Why?
| | Lymphokines | 1 | 1991 | 130 | 0.020 |
Why?
| | Qualitative Research | 1 | 2018 | 1640 | 0.020 |
Why?
| | Stroke | 1 | 1999 | 1225 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3185 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 6031 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1309 | 0.020 |
Why?
| | Autoradiography | 1 | 1989 | 64 | 0.020 |
Why?
| | Hospitalization | 1 | 1999 | 2346 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 1991 | 422 | 0.020 |
Why?
| | Brain Chemistry | 1 | 1989 | 117 | 0.020 |
Why?
| | Supranuclear Palsy, Progressive | 1 | 2008 | 18 | 0.020 |
Why?
| | Blindness | 1 | 2008 | 51 | 0.020 |
Why?
| | Saccades | 1 | 2008 | 45 | 0.020 |
Why?
| | Macaca mulatta | 1 | 1989 | 191 | 0.020 |
Why?
| | Glutamate Decarboxylase | 1 | 2008 | 165 | 0.020 |
Why?
| | Withholding Treatment | 1 | 2008 | 79 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2008 | 128 | 0.020 |
Why?
| | Frontal Lobe | 1 | 1989 | 159 | 0.020 |
Why?
| | Oculomotor Muscles | 1 | 2008 | 85 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 1991 | 474 | 0.020 |
Why?
| | Neural Inhibition | 1 | 2008 | 178 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 1991 | 1143 | 0.020 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2008 | 192 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1986 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1991 | 727 | 0.020 |
Why?
| | Pilot Projects | 1 | 2012 | 1858 | 0.010 |
Why?
| | Electromyography | 1 | 2008 | 416 | 0.010 |
Why?
| | Cranial Nerves | 1 | 2005 | 12 | 0.010 |
Why?
| | Sural Nerve | 1 | 2005 | 20 | 0.010 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2005 | 47 | 0.010 |
Why?
| | Graves Disease | 1 | 2005 | 30 | 0.010 |
Why?
| | Hypertrophy | 1 | 2005 | 131 | 0.010 |
Why?
| | Amino Acids | 1 | 1989 | 519 | 0.010 |
Why?
| | Axons | 1 | 2005 | 202 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3402 | 0.010 |
Why?
| | Myelin Sheath | 1 | 2005 | 167 | 0.010 |
Why?
| | Mice | 1 | 2020 | 18471 | 0.010 |
Why?
| | Contrast Sensitivity | 1 | 2000 | 15 | 0.010 |
Why?
| | Disease Progression | 1 | 2008 | 2874 | 0.010 |
Why?
| | Observer Variation | 1 | 2000 | 353 | 0.010 |
Why?
| | Reference Values | 1 | 2000 | 807 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2008 | 1809 | 0.010 |
Why?
| | Walking | 1 | 2000 | 561 | 0.010 |
Why?
| | Age Factors | 1 | 1999 | 3295 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1991 | 202 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 1991 | 78 | 0.010 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 102 | 0.010 |
Why?
| | Receptors, IgG | 1 | 1991 | 76 | 0.010 |
Why?
| | CD3 Complex | 1 | 1991 | 110 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 1991 | 100 | 0.010 |
Why?
| | Receptors, Fc | 1 | 1991 | 55 | 0.010 |
Why?
| | Pregnancy | 1 | 2003 | 7180 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 1991 | 335 | 0.000 |
Why?
| | Base Sequence | 1 | 1991 | 2188 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1991 | 2914 | 0.000 |
Why?
| | Gene Expression | 1 | 1991 | 1514 | 0.000 |
Why?
| | RNA | 1 | 1991 | 941 | 0.000 |
Why?
|
|
Pelak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|